Menu
Search
|

Menu

Close
X

Arbutus Biopharma Corp ABUS.OQ (NASDAQ Stock Exchange Global Select Market)

11.55 USD
+0.15 (+1.32%)
As of Jul 20
chart
Previous Close 11.40
Open 11.50
Volume 102,271
3m Avg Volume 96,919
Today’s High 11.95
Today’s Low 11.40
52 Week High 12.05
52 Week Low 3.20
Shares Outstanding (mil) 55.03
Market Capitalization (mil) 493.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
21.99
5.73
Price to Book (MRQ)
vs sector
4.27
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-51.57
14.61
Return on Equity (TTM)
vs sector
-55.72
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

100-8900 Glenlyon Pky
BURNABY   BC   V5J 5J8

Phone: +1604.4193200
Site:

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

SPONSORED STORIES